194 related articles for article (PubMed ID: 23939910)
1. Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.
Ammazzalorso A; De Filippis B; Giampietro L; Amoroso R
ChemMedChem; 2013 Oct; 8(10):1609-16. PubMed ID: 23939910
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors α antagonists.
Ammazzalorso A; Carrieri A; Verginelli F; Bruno I; Carbonara G; D'Angelo A; De Filippis B; Fantacuzzi M; Florio R; Fracchiolla G; Giampietro L; Giancristofaro A; Maccallini C; Cama A; Amoroso R
Eur J Med Chem; 2016 May; 114():191-200. PubMed ID: 26974385
[TBL] [Abstract][Full Text] [Related]
3. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Friedmann PS; Cooper HL; Healy E
Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
[TBL] [Abstract][Full Text] [Related]
5. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
6. An overview on biological mechanisms of PPARs.
Kota BP; Huang TH; Roufogalis BD
Pharmacol Res; 2005 Feb; 51(2):85-94. PubMed ID: 15629253
[TBL] [Abstract][Full Text] [Related]
7. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
Gani OA; Sylte I
J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
[TBL] [Abstract][Full Text] [Related]
8. The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists.
De Lellis L; Cimini A; Veschi S; Benedetti E; Amoroso R; Cama A; Ammazzalorso A
ChemMedChem; 2018 Feb; 13(3):209-219. PubMed ID: 29276815
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
10. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
11. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
Alemán G; Torres N; Tovar AR
Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
Giaginis C; Tsantili-Kakoulidou A; Theocharis S
Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
Guan Y
J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933
[TBL] [Abstract][Full Text] [Related]
14. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
Mirza AZ; Althagafi II; Shamshad H
Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
Smeets PJ; Planavila A; van der Vusse GJ; van Bilsen M
Acta Physiol (Oxf); 2007 Nov; 191(3):171-88. PubMed ID: 17935522
[TBL] [Abstract][Full Text] [Related]
16. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.
Dixit G; Prabhu A
Exp Mol Pathol; 2022 Feb; 124():104723. PubMed ID: 34822814
[TBL] [Abstract][Full Text] [Related]
17. PPARs: therapeutic targets for metabolic disease.
Berger JP; Akiyama TE; Meinke PT
Trends Pharmacol Sci; 2005 May; 26(5):244-51. PubMed ID: 15860371
[TBL] [Abstract][Full Text] [Related]
18. An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands.
Laghezza A; Piemontese L; Tortorella P; Loiodice F
Eur J Med Chem; 2019 Aug; 176():326-342. PubMed ID: 31112893
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
Aleshin S; Strokin M; Sergeeva M; Reiser G
Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
[TBL] [Abstract][Full Text] [Related]
20. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
